Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Heart Failure, Healthy Volunteer
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
- Trial name
- NCT03276728
- Testing
- AMG 986 IV, AMG 986 PO
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Amgen
Fontan Circulation, Single Ventricle Heart Disease
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.
- Conditions
- Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT06762964
- Testing
- Dapagliflozin tablet
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Exercise Capacity Improvement by Conduction System Pacing in heArt Failure patieNts Without Compelling CRT inDication
This randomized controlled trial aims to investigate the impact of conduction system pacing in comparison to right ventricular apical pacing on exercise capacity, as measured by peak oxygen uptake (VO2peak), in heart failure…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Conduction Disorder
- Trial name
- ESCPAND (NCT06278844)
- Testing
- Conduction system pacing, Right ventricular apical pacing
- Where
- Belgium
- Volunteers
- 75 people
- Sponsor
- University Hospital, Antwerp
Diastolic Heart Failure
Ranolazine in Diastolic Heart Failure
Patients with CAD and clinical symptoms of heart failure or patients with suspected heart failure with preserved ejection fraction (HFpEF) will be enrolled.
- Trial name
- RALI-DHF (NCT01163734)
- Testing
- Ranolazine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Cardiomyopathy, Diabetic
CARdiomyopathy in Type 2 DIAbetes Mellitus
The objective of the CARDIATEAM clinical study is to assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy using unsupervised clustering approaches based on deep phenotyping (clinical…
- Trial name
- CARDIATEAM (NCT04303364)
- Where
- 17 sites in France, Germany and 3 more
- Volunteers
- 1,256 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Atrial Fibrillation (AF), Hart Failure
Heart Failure Biomarkers
Systemic inflammation is closely associated with the development and progression of heart failure (HF). The study assessed the fibrin/albumin (FAR) ratio, a very important biomarker, as a prognostic indicator of HE.
- Trial name
- BIOHF (NCT06616038)
- Testing
- Data collection
- Where
- 2 sites in Italy
- Volunteers
- 114 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Heart Failure, Diastolic
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with…
- Trial name
- ROPA-DOP (NCT01901809)
- Testing
- Furosemide, Dopamine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Heart Failure With Preserved Ejection Fraction
AI-based Echocardiographic Quantification in Heart Failure
Heart failure (HF) is a clinical complication. About half of HF patients have heart failure with normal systolic fraction (HFpEF), and most of them are elderly women.
- Trial name
- NCT07010952
- Testing
- AI-based image analysis, AI-based imaging analysis
- Volunteers
- 3,000 people
- Sponsor
- Mackay Memorial Hospital
HFpEF - Heart Failure With Preserved Ejection Fraction
Role of Colchicine as Anti-Inflammatory Therapy in HFpEF
Heart failure with preserved ejection fraction (HFpEF) is a condition associated with high morbidity and mortality. Chronic low-grade inflammation plays a key role in its progression, yet few treatments specifically target this…
- Trial name
- CO-HFpEF (NCT06837623)
- Testing
- Colchicine Tablets
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Cairo University
HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
Tailored Exercise Training Study Among Adults With HFpEF
Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF.
- Trial name
- TEXPEF (NCT07223242)
- Testing
- Moderate-intensity continuous training (MCT), Resistance training, Weight loss
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure, Heart Failure, Systolic
Predicting Heart Failure Outcomes With Biomarkers and Imaging
This study aims to develop a better model to predict one-year risk of death in patients with heart failure. We will test whether combining information from routine blood tests (like NT-proBNP) and heart scans (measuring features…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- BIOPHF (NCT07332520)
- Volunteers
- 4,000 people
- Sponsor
- Xinjiang Medical University
Heart Failure With Preserved Ejection Fraction
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with…
- Trial name
- ENDEAVOR (NCT04986202)
- Testing
- AZD4831
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 711 people
- Sponsor
- AstraZeneca
Diastolic Heart Failure
Cardiac Resynchronisation Therapy Versus Rate-responsive Pacing in Heart Failure With Preserved Ejection Fraction
Half of patients with heart failure have normal heart pumping function (Heart failure with Preserved Ejection Fraction, HFpEF), most commonly characterised by breathlessness on exercise.
- Trial name
- PREFECTUS (NCT03338374)
- Testing
- Biventricular pacemaker
- Where
- 2 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- Cardiff and Vale University Health Board
Heart Failure With Preserved Ejection Fraction (HFpEF
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency
This study will investigate whether intravenous (IV) iron improves symptoms, exercise capacity, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency.
- Trial name
- ISLE HFpEF (NCT07643818)
- Testing
- Ferric Derisomaltose
- Where
- Jersey
- Volunteers
- 150 people
- Sponsor
- Government of Jersey
Heart Failure With Preserved Ejection Fraction
The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
The purpose of this study is to determine whether treatment with Ranolazine will improve exercise capacity in patients with Heart Failure with preserved left ventricular ejection fraction, or HFPEF.
- Trial name
- RAZE (NCT01505179)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Heart Failure, Diastolic
Respiratory Muscle Function in Heart Failure
This study is being done because investigators are trying to determine how respiratory muscle and lung function influence the exercise responses in heart failure and healthy participants.
- Trial name
- NCT03924479
- Testing
- PowerBreathe (Breathing muscle training)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction, Pulmonary Disease
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)
Heart failure with preserved ejection fraction (HFpEF) accounts for over 50% of heart failure cases in the United States, affecting a primarily elderly population.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
- Trial name
- NCT01354613
- Testing
- Dobutamine, Amlodipine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Cardiac TTR Amyloidosis
Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease
Cardiac amyloidosis is a multi-organ syndrome, which usually presents as restrictive cardiomyopathy (RCM). Transthyretin (TTR) amyloidosis (or ATTR) is a subtype of amyloidosis which frequently involves heart.
- Trial name
- NCT03098901
- Testing
- Tc99m-labeled pyrophosphate scan
- Volunteers
- 100 people
- Sponsor
- Kaplan Medical Center
Heart Failure With Preserved Ejection Fraction
The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF
The effectively therapeutic approaches for Heart failure with preserved ejection fraction (HFpEF) remain limited. The PARAGON-HF trial found that Angiotensin Receptor-Neprilysin Inhibition (ARNI) has potential benefits for the…
- Trial name
- ARNICFH (NCT05089539)
- Testing
- Angiotensin Receptor-Neprilysin Inhibition
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing Medical University
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- DUP-TIRZSEMA (NCT06914141)
- Testing
- Tirzepatide, Semaglutide
- Where
- United States
- Volunteers
- 28,118 people
- Sponsor
- Brigham and Women's Hospital